Cybin (OTCMKTS:CLXPF) Trading 5.9% Higher - Here's Why
Cybin Inc. (OTCMKTS:CLXPF) shares rose 5.9% during mid-day trading, reaching a high of $6.43 before closing at $6.26. Approximately 293,158 shares were traded, a 47% decline from the average daily volume. The company, with a market cap of $930.22 million, focuses on developing psychedelic therapeutics for psychiatric and neurological conditions. Analysts currently rate Cybin as a Hold, with some suggesting alternative stocks for investment.
Shares of Cybin Inc. (OTCMKTS:CLXPF - Get Free Report) were up 5.9% during mid-day trading on Thursday . The stock traded as high as $6.43 and last traded at $6.26. Approximately 293,158 shares were traded during trading, a decline of 47% from the average daily volume of 551,962 shares. The stock had previously closed at $5.91.
Cybin Price Performance
The company has a market cap of $930.22 million and a price-to-earnings ratio of -26.08. The firm has a 50-day moving average price of $8.36 and a 200 day moving average price of $9.13.
About Cybin
(Get Free Report)Cybin Inc, a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products.
Further Reading
- Five stocks we like better than Cybin
- Upcoming IPO Stock Lockup Period, Explained
- Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
- How to Start Investing in Real Estate
- Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
- How is Compound Interest Calculated?
- Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Cybin Right Now?
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
